Feds blame multistate B. cepacia outbreak on PharmaTech plant's water system

FDA sign

After a months-long investigation, federal officials have nailed down the source of a Burkholderia cepacia outbreak that made its way into several states and infected dozens of patients.

In an update Thursday, the Centers for Disease Control and Prevention and the FDA said they had detected the B. cepacia bacteria in the water system at Florida-based CMO PharmaTech. The company had produced 10 contaminated lots of constipation drug docusate sodium before 6 distributors shipped the meds around the country. In total, 60 people in 8 states became infected.

The agencies cleared the drug's active ingredient as a potential source, allowing healthcare providers to resume use of docusate sodium from other manufacturers.

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

The outbreak started in late June in ventilated cystic fibrosis patients. During the investigation, CDC officials said infections could be life-threatening in patients with compromised immune systems or lung conditions.

Back in July, PharmaTech recalled all lots of its Diocto Liquid after the FDA confirmed they had been contaminated. The company’s facility just passed an FDA inspection in March.

As the investigation unfolded last month, authorities announced they had placed India’s Laxachem on its import alert after the company refused to allow FDA officials to inspect its site. Among the APIs the company is believed to make is docusate sodium, officials said.

Back in 2012, federal officials had to wrestle a deadly outbreak that started at the now-defunct New England Compounding Center. And just this year, Pharmaceutical Innovations resolved federal criminal and civil cases for distributing contaminated ultrasound gel.

Related Articles:
FDA bans Indian API maker as it tracks source of Burkholderia cepacia outbreak
CMO expands drug recall over bacterial contamination concerns
CMO recalls constipation drug tied to bacterial infections reported in 5 states
Indictment of 14 at NECC includes murder charges
U.S. Marshals seize ultrasound gel containing dangerous levels of bacteria

Suggested Articles

Three facts about how distributors are managing in-demand inventory.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.

Purdue has reached an $8 billion settlement with the U.S. government to settle criminal and civil charges for its role in the U.S. opioid crisis.